Research Studies
Currently Enrolling Studies
MINT-E Study for Episodic Migraine (Study ID: M602011085)
Arizona Neuroscience Research is now enrolling participants in the MINT-C clinical trial, a Phase 3 study investigating Xeomin® (botulinum toxin type A) for the prevention of chronic migraine in adults.
About the Study:
This randomized, placebo-controlled trial evaluates whether Xeomin can reduce the number of migraine days experienced by participants. All qualified participants will receive Xeomin at some point during the study.
Duration: Up to 1 year
Visits: 14 total (including 8 remote telehealth visits)
Treatment: 4 injection sessions every 12 weeks
Compensation: Study-related care and medication provided at no cost
Eligibility:
Age 18 or older
Diagnosed with Episodic migraineÂ
Migraines began before age 50
Sponsor:
Merz Therapeutics GmbH
Trial Link: https://clinicaltrials.gov/study/NCT07018713
Click Here to Learn More: MINT-E - Arizona Neuroscience Research
MINT-C Study for Chronic Migraine (Study ID: M602011084)
Arizona Neuroscience Research is now enrolling participants in the MINT-C clinical trial, a Phase 3 study investigating Xeomin® (botulinum toxin type A) for the prevention of chronic migraine in adults.
About the Study:
This randomized, placebo-controlled trial evaluates whether Xeomin can reduce the number of migraine days experienced by participants. All qualified participants will receive Xeomin at some point during the study.
Duration: Up to 1 year
Visits: 14 total (including 8 remote telehealth visits)
Treatment: 4 injection sessions every 12 weeks
Compensation: Study-related care and medication provided at no cost
Eligibility:
Age 18 or older
Diagnosed with chronic migraineÂ
Migraines began before age 50
Sponsor:
Merz Therapeutics GmbH
Trial Link: https://clinicaltrials.gov/study/NCT07018713
Click here to Learn More: MINT-C - Arizona Neuroscience Research
Frexcite (EFC18098) – Frexalimab in RRMS/SPMS
Arizona Neuroscience Research is now enrolling participants in the Frexcite clinical trial, a Phase 3 study investigating frexalimab for relapsing and secondary progressive multiple sclerosis.
About the Study:
This is a bridging study evaluating the pharmacokinetics and safety of subcutaneous versus intravenous administration of frexalimab in adults with multiple sclerosis.
Eligibility:
See ClinicalTrials.gov or contact us for current criteria.
Sponsor: Sanofi
Volunteer Today: /volunteer-today/
Sanofi Frexalimab Pipeline: https://www.us.neurology.sanofimedical.com/our-neurology-pipeline/frexalimab
MyClad (MS7005680-0183) – Oral Cladribine in Generalized Myasthenia Gravis
Arizona Neuroscience Research is now enrolling participants in the MyClad clinical trial, a Phase 3 study evaluating oral cladribine in adults with generalized myasthenia gravis.
About the Study:
This is a randomized, double-blind, placebo-controlled study assessing the efficacy and safety of a new formulation of oral cladribine.
Eligibility:
Adults with generalized myasthenia gravis. See approved materials or contact us for details.
Sponsor: EMD Serono
Volunteer Today: /volunteer-today/
MyClad Study Website: https://www.mycladstudy.com/
Phases (P25-590) – Ubrelvy Observational Study in Migraine
Arizona Neuroscience Research is participating in the Phases (P25-590) observational study evaluating ubrogepant (Ubrelvy) in adults with migraine.
About the Study:
This is an observational study assessing changes in migraine attack severity in participants using oral ubrogepant.
Eligibility:
Adults with migraine. See sponsor-approved information.
Sponsor: AbbVie
Volunteer Today: /volunteer-today/
AbbVie Clinical Trials Page: https://abbvieclinicaltrials.com/study/P25-590
Â
Enable (TG1101-RMS406) – Real-World Experience with BRIUMVI in RMS
Arizona Neuroscience Research is now enrolling participants in the Enable clinical trial (TG1101-RMS406), a Phase 4 observational registry study evaluating real-world experience with BRIUMVI (ublituximab-xiiy) in adults with relapsing multiple sclerosis.
About the Study:
This longitudinal registry collects data on the safety, effectiveness, and patient experience of ublituximab in routine clinical practice over 96 weeks.
Eligibility:
Adults with relapsing forms of multiple sclerosis prescribed BRIUMVI. See approved materials for details.
Sponsor: TG Therapeutics
Volunteer Today: /volunteer-today/
ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06433752
Primrose (ZB020-03-001) – Orelabrutinib in Primary Progressive MS
Arizona Neuroscience Research is now enrolling participants in the Primrose clinical trial (ZB020-03-001), a Phase 3 study evaluating orelabrutinib in adults with primary progressive multiple sclerosis.
About the Study:
This is a global, randomized, double-blind, placebo-controlled Phase 3 trial assessing the efficacy and safety of orelabrutinib in PPMS.
Eligibility:
Adults 18 to 60 with primary progressive MS. See approved materials.
Sponsor: Zenas BioPharma
Volunteer Today: /volunteer-today/
Zenas BioPharma Pipeline: https://zenasbio.com/our-science/pipeline/
ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07067463
Monarch (ZB020-03-002) – Orelabrutinib in Secondary Progressive MS
Arizona Neuroscience Research is now enrolling participants in the Monarch clinical trial (ZB020-03-002), a Phase 3 study evaluating orelabrutinib in adults with non-active secondary progressive multiple sclerosis.
About the Study:
This is a global, randomized, double-blind, placebo-controlled Phase 3 trial assessing the efficacy and safety of orelabrutinib in SPMS.
Eligibility:
Adults with non-active secondary progressive MS. See approved materials.
Sponsor: Zenas BioPharma
Volunteer Today: /volunteer-today/
Zenas BioPharma Pipeline: https://zenasbio.com/our-science/pipeline/
ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07299019
Remaster (CLOU064P12301) – Remibrutinib in SPMS
Arizona Neuroscience Research is preparing to enroll participants in the Remaster clinical trial (CLOU064P12301), a Phase 3 study evaluating remibrutinib in adults with secondary progressive multiple sclerosis.
About the Study:
This is a randomized, double-blind, placebo-controlled Phase 3 trial assessing the efficacy and safety of remibrutinib in SPMS.
Eligibility:
Adults with secondary progressive MS. See approved materials or contact us for current status.
Sponsor: Novartis
Volunteer Today: /volunteer-today/
Novartis Clinical Trial Page: https://www.novartis.com/clinicaltrials/study/nct07225504
ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07225504
